tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Van Thiel DH et al. | Gastrointestinal and metabolic problems associated with immunosuppression with either CyA or FK 506 in liver transplantation. | 1990 | Transplant. Proc. | pmid:1689893 |
| Mieles L et al. | Oral glucose tolerance test in liver recipients treated with FK 506. | 1990 | Transplant. Proc. | pmid:1689894 |
| Alessiani M et al. | Infections with FK 506 immunosuppression: preliminary results with primary therapy. | 1990 | Transplant. Proc. | pmid:1689895 |
| Staschak S et al. | A cost comparison of liver transplantation with FK 506 or CyA as the primary immunosuppressive agent. | 1990 | Transplant. Proc. | pmid:1689896 |
| Second International Workshop on FK 506. A potential breakthrough in immunosuppression: clinical implications. October 31, 1989, Barcelona, Spain. Proceedings. | 1990 | Transplant. Proc. | pmid:1689897 | |
| Cadoff EM et al. | Assay of FK 506 in plasma. | 1990 | Transplant. Proc. | pmid:1689898 |
| Venkataramanan R et al. | Pharmacokinetics of FK 506: preclinical and clinical studies. | 1990 | Transplant. Proc. | pmid:1689899 |
| Jain AB et al. | Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. | 1990 | Transplant. Proc. | pmid:1689900 |
| Fung JJ et al. | Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. | 1990 | Transplant. Proc. | pmid:1689901 |
| Saitoh Y et al. | Morphological rejection phases and cytotoxic activity in peripheral blood lymphocytes in canine lung allo-transplantation. | 1990 | Jpn J Surg | pmid:1692892 |
| Rosen MK et al. | Inhibition of FKBP rotamase activity by immunosuppressant FK506: twisted amide surrogate. | 1990 | Science | pmid:1693013 |
| Thomas FT et al. | Comparative efficacy of immunosuppressive drugs in xenografting. | 1990 | Transplant. Proc. | pmid:1693452 |
| Harrison RK and Stein RL | Substrate specificities of the peptidyl prolyl cis-trans isomerase activities of cyclophilin and FK-506 binding protein: evidence for the existence of a family of distinct enzymes. | 1990 | Biochemistry | pmid:1693856 |
| Starzl TE et al. | Kidney transplantation under FK 506. | 1990 | JAMA | pmid:1693970 |
| Bierer BE et al. | Mechanisms of immunosuppression by FK506. Preservation of T cell transmembrane signal transduction. | 1990 | Transplantation | pmid:1694317 |
| Eiras G et al. | Species differences in sensitivity of T lymphocytes to immunosuppressive effects of FK 506. | 1990 | Transplantation | pmid:1694318 |
| Tze WJ et al. | In vitro effects of FK-506 on human and rat islets. | 1990 | Transplantation | pmid:1694319 |
| Maki N et al. | Complementary DNA encoding the human T-cell FK506-binding protein, a peptidylprolyl cis-trans isomerase distinct from cyclophilin. | 1990 | Proc. Natl. Acad. Sci. U.S.A. | pmid:1695378 |
| Doe SE et al. | Early effects of the immunosuppressive drug FK-506 on signal transduction in lymphocytes. | 1990 | Biochem. Soc. Trans. | pmid:1695581 |
| Suzuki S et al. | In vivo 31P nuclear magnetic resonance findings on heterotopically allografted hearts in rats treated with a novel immunosuppressant, FK506. | 1990 | Heart Vessels | pmid:1699922 |
| Bierer BE et al. | Probing immunosuppressant action with a nonnatural immunophilin ligand. | 1990 | Science | pmid:1700475 |
| Murase N et al. | FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in rats. | 1990 | Transplantation | pmid:1700504 |
| Burke MD et al. | Inhibition of the metabolism of cyclosporine by human liver microsomes by FK506. | 1990 | Transplantation | pmid:1700507 |
| Wicker LS et al. | Suppression of B cell activation by cyclosporin A, FK506 and rapamycin. | 1990 | Eur. J. Immunol. | pmid:1700753 |
| Sigal NH et al. | Observations on the mechanism of action of FK-506. A pharmacologic probe of lymphocyte signal transduction. | 1990 | Biochem. Pharmacol. | pmid:1700909 |
| Hara S et al. | The effects of a new immunosuppressive agent, FK506, on the glomerular injury in rats with accelerated nephrotoxic serum glomerulonephritis. | 1990 | Clin. Immunol. Immunopathol. | pmid:1700936 |
| Murase N et al. | Effect of FK 506 on spontaneous diabetes in BB rats. | 1990 | Diabetes | pmid:1700959 |
| Akutsu I et al. | [Inhibitory effect of FK-506 on the development of late asthmatic response and on the increased bronchial responsiveness]. | 1990 | Arerugi | pmid:1705791 |
| Mochizuki M and Kawashima H | Effects of FK506, 15-deoxyspergualin, and cyclosporine on experimental autoimmune uveoretinitis in the rat. | 1990 | Autoimmunity | pmid:1717007 |
| Ni M et al. | FR900506 (FK506) and 15-deoxyspergualin (15-DSG) modulate the kinetics of infiltrating cells in eyes with experimental autoimmune uveoretinitis. | 1990 | Autoimmunity | pmid:1717008 |
| Wasik M et al. | Effect of FK-506 and cyclosporine on human T and B lymphoproliferative responses. | 1990 Jul-Aug | Immunopharmacology | pmid:1699911 |
| MacLeod AM and Thomson AW | [FK-506. A new immunosuppressive drug]. | 1990 Jul-Sep | Medicina (Firenze) | pmid:1706817 |
| Naouri A and Tissot E | [Indications for liver transplantation in adults]. | 1990 Jun-Jul | J Chir (Paris) | pmid:1698800 |
| Gailliot FP et al. | Fluidized bed adsorption for whole broth extraction. | 1990 Sep-Oct | Biotechnol. Prog. | pmid:1366874 |
| Blackham A and Griffiths RJ | The effect of FK506 and cyclosporin A on antigen-induced arthritis. | 1991 | Clin. Exp. Immunol. | pmid:1718639 |
| Carobbi A et al. | Effect of splenectomy in combination with FK 506 and 15-deoxyspergualin on cardiac xenograft survival. | 1991 | Transplant. Proc. | pmid:1703704 |
| Jain AB et al. | Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721270 |
| Abu-Elmagd KM et al. | Four-hour versus 24-hour intravenous infusion of FK 506 in liver transplantation. | 1991 | Transplant. Proc. | pmid:1721271 |
| Abu-Elmagd KM et al. | Strategy of FK 506 therapy in liver transplant patients: effect of graft function. | 1991 | Transplant. Proc. | pmid:1721272 |
| Ericzon BG et al. | Pharmacokinetics of FK 506 during maintenance therapy in liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721273 |
| Jain AB et al. | Pharmacokinetics of cyclosporine and nephrotoxicity in orthotopic liver transplant patients rescued with FK 506. | 1991 | Transplant. Proc. | pmid:1721274 |
| DiLella AG and Craig RJ | Characterization of the human FKBP-12 gene and related pseudogenes. | 1991 | Transplant. Proc. | pmid:1721302 |
| Kar S and Carr B | Gene expression of FK 506-binding protein. | 1991 | Transplant. Proc. | pmid:1721303 |
| Connelly PR | Thermodynamics of interaction of FK 506-binding protein and its ligands. | 1991 | Transplant. Proc. | pmid:1721304 |
| Donnelly JG and Soldin SJ | Purification of a 50- to 58-kDa immunophilin from human spleen and a Jurkat T-cell line capable of binding cyclosporine A, FK 506, and rapamycin. | 1991 | Transplant. Proc. | pmid:1721305 |
| Rosborough SL et al. | Identification of FKBP-related proteins with antibodies of predetermined specificity and isolation by FK 506 affinity chromatography. | 1991 | Transplant. Proc. | pmid:1721306 |
| Winkler M et al. | Use of FK 506 for treatment of chronic rejection after liver transplantation. | 1991 | Transplant. Proc. | pmid:1721334 |
| D'Alessandro AM et al. | FK 506 rescue therapy for resistant rejection episodes in liver transplant recipients. | 1991 | Transplant. Proc. | pmid:1721335 |
| Lewis WD et al. | FK 506 rescue therapy in liver transplant recipients with drug-resistant rejection. | 1991 | Transplant. Proc. | pmid:1721336 |
| Woodle ES et al. | FK 506: reversal of humorally mediated rejection following ABO-incompatible liver transplantation. | 1991 | Transplant. Proc. | pmid:1721337 |
| Shaw BW et al. | FK 506 for rescue treatment of acute and chronic rejection in liver allograft recipients. | 1991 | Transplant. Proc. | pmid:1721338 |
| McDiarmid SV et al. | FK 506 rescue therapy in liver transplantation: outcome and complications. | 1991 | Transplant. Proc. | pmid:1721339 |
| Offner G et al. | FK 506 in a 14-year-old renal allograft recipient with cyclosporine-related liver nephrotoxicity: 1-year follow-up. | 1991 | Transplant. Proc. | pmid:1721366 |
| Imai K et al. | Histopathological study of canine pancreaticoduodenal allotransplantation with FK506, cyclosporine, and triple regimen immunosuppression. | 1991 | Transplant. Proc. | pmid:1703347 |
| Japanese study of FK 506 on kidney transplantation: the benefit of monitoring the whole blood FK 506 concentration. Japanese FK 506 Study Group. | 1991 | Transplant. Proc. | pmid:1721367 | |
| Starzl TE et al. | Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. | 1991 | Transplant. Proc. | pmid:1703351 |
| Darras FS et al. | Transplantation of pediatric en bloc kidneys under FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721368 |
| Shapiro R et al. | Kidney transplantation under FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1703352 |
| Todo S et al. | Clinical small bowel or small bowel plus liver transplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1721369 |
| Tzakis AG et al. | Use of FK 506 in pediatric patients. | 1991 | Transplant. Proc. | pmid:1703353 |
| Fries D et al. | Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation. | 1991 | Transplant. Proc. | pmid:1721370 |
| Jain AB et al. | Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1703354 |
| DiMartini A et al. | Psychiatric morbidity in liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721399 |
| Lopez OL et al. | Neuropathologic findings in liver transplantation: a comparative study of cyclosporine and FK 506. | 1991 | Transplant. Proc. | pmid:1721400 |
| Viebahn R et al. | Hypoxic and reoxygenation injury in human and rat hepatocytes--influence of FK 506 and cyclosporine. | 1991 | Transplant. Proc. | pmid:1721401 |
| Brabletz T et al. | The immunosuppressives FK 506 and cyclosporin A inhibit the generation of protein factors binding to the two purine boxes of the interleukin 2 enhancer. | 1991 | Nucleic Acids Res. | pmid:1707162 |
| de Bruin RW et al. | Fulminant graft-versus-host disease after FK 506 treatment in fully allogeneic small bowel transplantation. | 1991 | Transplant. Proc. | pmid:1721429 |
| Iwaki Y et al. | Replacement of donor lymphoid tissue in small-bowel transplants. | 1991 | Lancet | pmid:1707470 |
| Langrehr JM et al. | FK 506 inhibits nitric oxide production by cells infiltrating sponge matrix allografts. | 1991 | Transplant. Proc. | pmid:1721430 |
| Markus PM et al. | Effects of in vivo treatment with FK506 on natural killer cells in rats. | 1991 | Transplantation | pmid:1707562 |
| Gotoh M et al. | Tolerance induction by liver grafting and FK 506 treatment in nonhuman primates. | 1991 | Transplant. Proc. | pmid:1721431 |
| Lin CS et al. | FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes. | 1991 | Cell. Immunol. | pmid:1707760 |
| Valdivia LA et al. | Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721432 |
| Vincent SH et al. | Effects of the immunosuppressant FK-506 and its analog FK-520 on hepatic and renal cytochrome P450 mixed-function oxidase. | 1991 | Biochem. Pharmacol. | pmid:1708254 |
| Wu GD et al. | FK 506 inhibits the development of transplant arteriosclerosis. | 1991 | Transplant. Proc. | pmid:1721433 |
| Markus PM et al. | FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. | 1991 | Surgery | pmid:1713358 |
| Deguchi K et al. | Effects of FK 506 on acute experimental allergic encephalomyelitis. | 1991 | Transplant. Proc. | pmid:1721461 |
| Farley DE et al. | The effect of two new immunosuppressive agents, FK506 and didemnin B, in murine pregnancy. | 1991 | Transplantation | pmid:1713360 |
| Bolton C | The ability of myelin basic protein-sensitised leukocytes to adoptively transfer experimental allergic encephalomyelitis following coculture with FK 506, cyclosporine, or prednisolone. | 1991 | Transplant. Proc. | pmid:1721462 |
| Vathsala A et al. | The immunosuppressive antagonism of low doses of FK506 and cyclosporine. | 1991 | Transplantation | pmid:1713361 |
| McManus BM et al. | Impact of FK 506 on myocarditis in the enteroviral murine model. | 1991 | Transplant. Proc. | pmid:1721463 |
| Kawano K et al. | A protective effect of FK506 in ischemically injured rat livers. | 1991 | Transplantation | pmid:1713362 |
| Nossal GJ | Summary of the First International FK 506 Congress: perspectives and prospects. | 1991 | Transplant. Proc. | pmid:1721464 |
| Armitage JM et al. | Preliminary experience with FK506 in thoracic transplantation. | 1991 | Transplantation | pmid:1713363 |
| Staruch MJ et al. | Differential effects of the immunosuppressive macrolides FK-506 and rapamycin on activation-induced T-cell apoptosis. | 1991 | Int. J. Immunopharmacol. | pmid:1721613 |
| Altmeyer A et al. | Unexpected up-regulation of gene expression by cyclosporin A and FK-506 in a T-cell lymphoma: both immunosuppressants augment Ly-6E antigen induction by interferon-gamma in the presence of ionomycin. | 1991 | Int. J. Immunopharmacol. | pmid:1726093 |
| Gordon RD et al. | Liver transplantation at the University of Pittsburgh, 1984 to 1990. | 1991 | Clin Transpl | pmid:1726458 |
| Ryu S and Yasunami Y | The necessity of differential immunosuppression for prevention of immune rejection by FK506 in rat islet allografts transplanted into the liver or beneath the kidney capsule. | 1991 | Transplantation | pmid:1718064 |
| Kuroki H et al. | Morphological and immunological analysis of rats with long-term-surviving limb allografts induced by a short course of FK 506 or cyclosporine. | 1991 | Transplant. Proc. | pmid:1703697 |
| Jamieson NV et al. | Orthotopic liver transplantation at Addenbrooke's Hospital Cambridge 1968 to 1991. | 1991 | Clin Transpl | pmid:1726459 |
| Starzl TE et al. | Hepatotrophic properties in dogs of human FKBP, the binding protein for FK506 and rapamycin. | 1991 | Transplantation | pmid:1718068 |
| Morris RE et al. | Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions. | 1991 | Transplant. Proc. | pmid:1703698 |
| Takahara S et al. | Survival of cardiac allograft in highly sensitized and nonsensitized rats treated with FK506. | 1991 | J Clin Lab Immunol | pmid:1726566 |
| Lane WS et al. | Complete amino acid sequence of the FK506 and rapamycin binding protein, FKBP, isolated from calf thymus. | 1991 | J. Protein Chem. | pmid:1718307 |
| Goto S et al. | Effect of FK 506 and cyclosporine on heart allograft survival in rats. | 1991 | Transplant. Proc. | pmid:1703700 |
| Stötter H and Lotze MT | Human lymphokine-activated killer cell activity. Role of IL-2, IL-4, and IL-7. | 1991 | Arch Surg | pmid:1726819 |
| James DG | Which immunomodulator? | 1991 | Br J Clin Pract | pmid:1718384 |
| Flavin T et al. | Initial experience with FK 506 as an immunosuppressant for nonhuman primate recipients of cardiac allografts. | 1991 | Transplant. Proc. | pmid:1703701 |
| Karlsson H and Nässberger L | FK506 lacks the ability to inhibit expression of interleukin-2 receptor beta-chain on human lymphocytes. | 1991 | J Clin Lab Immunol | pmid:1726895 |
| Jiang H et al. | Effect of FK 506 on heart allograft survival in highly sensitized recipient rats in comparison with cyclosporine. | 1991 | Transplant. Proc. | pmid:1703702 |